• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies

    Waters Corp. Acquires Light Scattering Company Wyatt Technology
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Syngene International Ltd.

    Quotient Sciences

    Societal CDMO

    Federal Equipment Company
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Syngene International Ltd.

    Quotient Sciences

    Societal CDMO

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biosimilar Market Trends

    2017 was a record year for biosimilar approvals.

    Biosimilar  Market Trends
    Fiona Greer and Bruno Speder, SGS09.11.18
    Biosimilars have now become commonplace in the clinic in many European countries. The first biosimilar product, Sandoz’s Omnitrope, a version of Lilly’s Humatrope (somatropin), was approved by the EMA in 2006 and, in the decade that followed, more than 20 biosimilars gained regulatory approval. The first biosimilar monoclonal antibody, to Janssen’s Remicade (infliximab) was approved in 2013. However, 2017 was a record year for such products, with 16 approvals for biosimilars referencing seven different innovator drugs. By mid-2018, EMA had approved over 40 biosimilars in total since 2006.

    The U.S. has been much slower off the mark in this field. The FDA’s 351(k) pathway for biosimilar approval, part of the Biologics Price Competition and Innovation (BPCI) Act, was agreed in 2010, and draft guidance documents published two years later. It was not until 2015 though that Sandoz’s Zarxio, a biosimilar of Amgen’s Neupogen (filgrastim), was given the go-ahead for marketing using this pathway—outside of the U.S. the product is marketed under the brand name Zarzio. Multiple biosimilars to Neupogen had already been licensed in Europe, prior to the U.S. approval of Zarxio.

    Since then, there has been a rapid acceleration in the pace of approvals with five in 2017, although legal and patent issues are still preventing some biosimilars accessing the U.S. market. Several of the big pharmaceutical companies have made substantial investments in developing further biosimilars, and many marketing authorization applications, particularly of monoclonal antibodies, are awaiting consideration by the FDA.

    A biosimilar could be seen as a generic biologic product by some. However, this is not an accurate view, as biomolecules are ‘manufactured’ from living material and have a much more complex and intricate structure than small-molecule synthetic drugs. This is acknowledged in the requirements of various regulatory guidelines and pathways, which are somewhat more complex than for small-molecule generics. The path to market for a biosimilar involves a so-called “abbreviated” approval process, whereby a Phase II clinical trial is not required. Instead, there is intense focus on proving ‘biosimilarity’ to the reference originator product using a combination of physicochemical, biological and clinical data which is not required for a novel product.

    Although the biosimilar will offer cost savings to patients over the originator product, in practice the price differential is unlikely to be quite as great as is the case for small-molecule generics. A clue to the other significant difference is in the name, biosimilar. The active ingredient in a small molecule generic has to be identical to that of the originator. However, for biosimilars, this is not achievable due to the different biological manufacturing processes. Even different batches of any originator biologic will have slight variations. Rather, the biosimilar product will be within the acceptable range of product attributes of the original biological but not exactly identical, hence the name ‘biosimilar.’ There will, inevitably, be some slight differences in structure between the two as a result of the different manufacturing process employed and hence the biosimilar producer must prove to the regulatory authorities that these structural differences have no influence on the safety and efficacy of the biosimilar compared to the originator.

    Another important consideration is the selection of the indication for which approval will be sought. Many biologics, particularly monoclonal antibodies, are marketed for a number of different indications, so there is a decision to be made at the outset about which one offers the best route to initial approval.

    If biosimilarity has been demonstrated in one indication, then it is possible that, with appropriate scientific justification, it could be extrapolated to the other indications for which the originator product is marketed. However, this is not a given.

    Generation of the supporting CMC dossier for biosimilars
    The Chemistry, Manufacturing and Control (CMC) dossier is an essential part of the submission package for a clinical trial and, in a later stage, for an application for market authorization for any pharmaceutical product. In the case of a biosimilar, the CMC part is even more important. The dossier must include a comprehensive head-to-head comparison of the biosimilar and the originator product. As part of this comparison, physicochemical and biological characterization is carried out on multiple batches of both the biosimilar and the originator in order to establish whether any differences exist. It is important that further investigation is then carried out to examine the possible impact of these differences on the safety and efficacy of the product. The dossier has to indicate where the differences between the two products are, and how these will potentially affect the performance of the biosimilar product. It will also include all details of the analytical and other methods that have been used to identify these differences. This will allow the assessor to decide just how “similar” the two products actually are. This comparison is the core part of the CMC dossier for a biosimilar.

    The document should also include details of how the product was manufactured, including any cell lines that were used, and details such as the sources of all materials that went into the bioreactor. A description of the process control methods used must also be included, plus information about how the analytical data have been validated. All of this information will need to be included in any CMC dossier, regardless of whether it is for a small molecule or a biologic, a generic or a biosimilar.

    The head-to-head comparison is an additional requirement for a biosimilar, and performing this is not a trivial endeavor. CMC data and product specification ranges are rarely available for originator products, which, in any case, may have changed during their ‘life time’ due to manufacturing changes that have been authorized, so the entire analytical exercise has to be performed many times on different batches to establish ranges of quality attributes to enable comparison to be made. This is a relatively costly process, and locating a source of the originator product batches can prove extremely difficult.

    A comprehensive set of preclinical safety studies must also be carried out before any human volunteers or patients are dosed with the biosimilar drug candidate. These will include in-vitro assays and for some regulatory authorities, appropriate animal models designed to predict whether those small differences may have an impact on either the safety or efficacy of the product.

    Immunogenicity is a particular concern, and both in-silico tools and in-vitro assessments using animal tissue can be used to predict whether it is likely to occur in humans. Some regulations require that animal immunogenicity studies be carried out before humans are dosed for the first time.

    Biosimilar phase I studies
    For an originator product, Phase I studies will typically be carried out on 30-48 healthy volunteers to establish its safety. The study group for a biosimilar Phase I study, in contrast, will involve between 120 and 200 healthy volunteers. The discrepancy arises not because the trial is looking to establish primary safety, but because it is designed to detect any differences in safety signals between the biosimilar and the originator product. Although the structural differences between the two products could be very small, they still introduce a potential risk, and even though analytical and preclinical animal studies may indicate that there should not be any differences in humans between the originator and the biosimilar, the Phase I study is necessary to show that the new product is safe but also, importantly, that it is just as safe as the originator. This requires statistical calculations, and for these calculations to be meaningful and valid, a larger group of subjects is required.

    Some countries have proven to be better locations than others for carrying out these studies. It is important to select a location where the local health authorities and ethics committees understand what the aims of a Phase I biosimilar study are, and why so many subjects are required. The subjects will receive either the originator product, for which safety data are already available, and a safety profile established; or they will be dosed with the biosimilar, for which the safety profile is not certain.

    There is a small, but potential chance that those small structural differences—or another minuscule difference that had not been detected in the analytical or preclinical work—could cause a major adverse event, such as an immune cascade. It could be argued whether it is ethically acceptable to expose healthy volunteers to these risks, in order to test a product that is essentially a copy of something that is already on the market, and for which the medical added value might be debatable. That said, the best place to run a study of this nature is in a country where there is already a good Phase I infrastructure, and a favorable regulatory environment where the timelines for study approval are not too long, such as the UK, Belgium, the Netherlands, and the U.S.

    At the outset, it is important to open discussions with the relevant regulatory authority, to establish the acceptability of the study design and whether, based on the CMC dossier, the product may be considered biologically similar to the originator. If not, then there is little point in continuing with further development of the drug candidate as a biosimilar.

    As well as the Phase I comparative safety study, a Phase III study proving equivalent efficacy will be required. It is again important to discuss the design of this study with the regulator, and together establish what endpoints will be required. The study needs to be carried out in a representative patient population and to be sufficiently well powered in terms of patient numbers to ensure that it is sensitive enough to detect any potential differences in efficacy between the two products.

    In the U.S., the additional aspect of interchangeability needs to be established, whereas in the EU, there are important questions of pricing and reimbursement to be addressed. As with any application for a drug approval, discussions with the regulators will be required regarding the inevitable data differences that are observed, and how they should best be managed. If any deviations are being made from the reference product, such as its strength, the pharmaceutical form, or formulation, these will need to be justified to the regulator. However, it is important to note that the route of administration must be the same as for the reference product.

    Some changes will not be compatible with biosimilarity, as they change the chemical nature of the product too much. Changes designed to improve safety may not preclude a biosimilar decision, however; these might include lower levels of known impurities than are present in the reference product or a reduction in its immunogenicity.

    Case study: a change of clinical trial location
    As an example of the difficulty in gaining approval to carry out a Phase I biosimilar study, a large generics company was looking to start a trial for a biosimilar to a monoclonal antibody drug. However, the proposed trial was rejected in the Netherlands.

    The key to gaining the go-ahead to run this trial was twofold: completely reworking the CMC dossier; and applying to run the trial in a different country. The changes to the dossier used available information but provided an additional head-to-head comparison of analytical data. This was submitted to the health authority in Belgium, which gave the trial the green light within 15 days.

    Conclusion: careful documentation wins the regulators over!
    As more biosimilars reach the market, regulators will become more experienced and familiar with the concept of the biosimilar Phase I study. However, convincing them that the study will not put volunteers at risk will, quite rightly, remain an essential part of the process. Clear, careful documentation of the analytical and preclinical studies that have been carried out and open dialogue with regulators will go a long way in providing that reassurance. 
    Related Searches
    • it
    • biologics
    • Preclinical
    • fda
    Suggested For You
    Inhaled Drug Delivery Technology Trends Inhaled Drug Delivery Technology Trends
    Mogene Mogene
    Lilly Appoints SVP, Oncology President Lilly Appoints SVP, Oncology President
    Boehringer Provides CMC Services for CANbridge Boehringer Provides CMC Services for CANbridge
    ViroMed Secures DNA Production Facility in the U.S. ViroMed Secures DNA Production Facility in the U.S.
    Why Otsuka Outsourced Regulatory Affairs Why Otsuka Outsourced Regulatory Affairs
    WuXi STA, Antengene Ink Mfg. Pact WuXi STA, Antengene Ink Mfg. Pact
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    Rockwell Medical Announces FDA Approval Rockwell Medical Announces FDA Approval
    05	Merck 05 Merck
    12	AstraZeneca 12 AstraZeneca
    10	Lilly 10 Lilly
    ProBioGen, Pionyr in Devt. and Mfg. Pact ProBioGen, Pionyr in Devt. and Mfg. Pact
    Journeying with CROs: Driving drug development efficiency Journeying with CROs: Driving drug development efficiency
    Arcinova Appoints CSO Arcinova Appoints CSO

    Related Online Exclusives

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Promotions & Moves
      Lilly Appoints SVP, Oncology President

      Lilly Appoints SVP, Oncology President

      White brings more than 25 years of experience in the pharmaceutical industry
      08.31.18


    • Bio News | Breaking News | cGMP Manufacture | Clinical Trial Materials | Collaborations & Alliances | Industry News
      Boehringer Provides CMC Services for CANbridge

      Boehringer Provides CMC Services for CANbridge

      Supplies clinical material manufactured in China for new cancer drug
      08.27.18

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Drug Development | Facilities | Industry News
      ViroMed Secures DNA Production Facility in the U.S.

      ViroMed Secures DNA Production Facility in the U.S.

      Reinforcing readiness for BLA submission and market launch of its proprietary DNA-based lead product
      08.21.18

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Astellas To Transfer Manufacturing Plant To Delpharm
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Thermo Fisher Expands Steriles Facility In Asia-Pacific Region
    • Lifecore Biomedical Enters Into $150M New Financing Deal
    Breaking News
    • Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    • JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    • Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    • Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    • Waters Corp. Acquires Light Scattering Company Wyatt Technology
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    BGG Receives Patent for Saw Palmetto ID Method
    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Coatings World

    Latest Breaking News From Coatings World

    Brand Finance: Post-COVID Recovery Slows for Chemicals Industry Battling Energy Crisis
    BCF Calls for Greater Urgency on REACH Impasse
    MNYCA Hosts Afternoon Baseball Event
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CareDx, Miromatrix Collaborate on Bioengineered Organs Research
    Capitainer Releases to Market its Fully Automated Sample Handler
    Titan Medical Licenses Most IP to Intuitive; CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Stetson Introduces Men’s Grooming Portfolio
    Two Executives Depart from Unilever Amid CEO Transition
    L’Oréal Paris Welcomes Thuso Mbedu as Brand Ambassador
    Happi

    Latest Breaking News From Happi

    Beautycounter Appoints Board Director Mindy Mackenzie Interim CEO
    Unilever Ventures’ Backs Selva Ventures in $34 Million Fund for Early-Stage CPG Brands
    Two Executives Depart from Unilever Amid CEO Transition
    Ink World

    Latest Breaking News From Ink World

    ACTEGA, Makro Labelling to Advance Signite Technology
    BCF Requests Greater Urgency on REACH Impasse
    Updated Method Published for Entire BASF Product Portfolio
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ACTEGA teams with Makro Labelling to advance Signite technology
    Constantia Flexibles and SB Packagings commence joint venture
    Inland donates new VersaStudio printer to local high school
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mann+Hummel Names President Air Filtration Americas
    KNH Launches Eco-Friendly Menstrual Pads
    Niine Introduces India's First PLA-Based Sanitary Pads
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Enrollment Completed in Anika Therapeutics' Hyalofast Study
    Exactech Releases Next-Gen GPS Shoulder
    Data Shows Favorable Survivorship of MISHA Knee System & Reduction of Arthroplasty Risk in Patients
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Presents Path to Accelerate Revenue Growth
    STMicroelectronics Introduces Waterproof MEMS Pressure Sensor
    Graphene Flagship to Join Euro Nano Forum 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login